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P53Somatic mitochondrial DNA alterations have been found in all types of cancer. To better understand the role
of mitochondria and their involvement in the pathogenic mechanisms of cancer development, the effects of
cancer mitochondria were investigated in a deﬁned nuclear background using a transmitochondrial cybrid
system. Our results demonstrated that cancer mitochondria confer a signiﬁcant reduction in cell growth
when cells are metabolically stressed in a galactose medium. Activities of the respiratory chain complexes,
cellular oxygen consumption, and ATP synthesis rates were found to be much lower in breast cancer cells,
than those in normal breast epithelial cells of MCF-10A (10A). These results suggest that there is reduced
mitochondrial function in the studied breast cancer cell lines. Similarly reduced mitochondrial function was
observed in cybrids containing cancer mitochondria. Novel tRNA mutations were also identiﬁed in two
breast cancer cell lines, possibly responsible for the observed mitochondrial dysfunction. We conclude that
altered mitochondria in cancer cells may play a crucial role in tumor development.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
Cancer cells adapt to hypoxic and acidic conditions generated
during progressive tumor cell growth by shifting the burden of energy
metabolism from mitochondrial oxidative phosphorylation to glyco-
lysis [1]. Although the molecular pathogenic mechanism is currently
unknown, it is expected that mitochondria play a crucial role in this
transition.
The major function of mitochondria is the generation of ATP, the
energy currency of the cell, by oxidative phosphorylation. During this
process reactive oxygen species (ROS) are produced. ROS can cause
oxidative DNA damage and increase tumorigenicity [2,3] as well as
metastatic ability [4–6]. Thus, mitochondria could play an important
role in multiple steps of tumor development. Mitochondrial dysfunc-
tion, one of the most notable features of cancer cells, can be caused by
molecular defects in mitochondrial or nuclear genes that encode
proteins involved in mitochondria biogenesis; respiratory chain
assembly and function; maintenance of membrane potential; and
energy metabolic or signal transducing pathways.
Somatic alterations in mitochondrial DNA (mtDNA) are commonly
found in 30–100% of all tumors studied, including breast cancer [7–11].
However, most of these somatic mtDNA alterations are neutral variants
without any functional relevance [7–11]. ThesemtDNA alterations may
simply reﬂect the genomic instability of tumor cells. On the other hand,+1 713 798 8937.
ll rights reserved.cancerous mitochondria may contain a collection of somatic mtDNA
mutations, each present at a level of heteroplasmy below current
detection limits. Nonetheless, a small number of deleterious mtDNA
mutations that result in alteredmitochondrial function have been found
[12–15].
Despite the large volume of reports documenting somatic mtDNA
alterations in cancer cells, studies of the roles of the altered
mitochondrial genome in tumor development have been scarce. In
order to investigate the contribution of defective mitochondria to
cancer, the effect of nuclear genes must be excluded [16,17]. Using
transmitochondrial cybrids, mitochondria carrying a homoplasmic
pathogenic point mutation (m.8993TNG in ATP6) were studied in
prostate cancer cell lines [18,19]. This mutant mtDNA also conferred an
advantage in the early stage of tumor growth when transplanted into
nude mice [18,19]. A recent report demonstrated that defective
oxidative phosphorylation in thyroid oncocytic carcinoma was asso-
ciated with combined complex I/III deﬁciency by the identiﬁcation of
mtDNA mutations in genes encoding a complex I subunit and
cytochrome b [15]. Meanwhile, Matoba et al. have shown that P53,
one of the most frequently mutated genes in cancers, modulates the
balance between the two major energy production pathways: aerobic
mitochondrial respirationand anaerobic glycolysis [20]. Themodulation
by P53 was mediated by a protein responsible for the assembly of
complex IV [20]. In P53−/− cells, cytochrome c oxidase activity was
found to be reduced [20,21]. These observations suggest that the down
regulation of mitochondrial respiratory function in cancer cells may be
achieved by mutations in the nuclear genome, in the mitochondrial
genome or in both genomes.
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characterized the mitochondrial function in breast cancer cell lines
and in their transmitochondrial cybrids using biochemical and molec-
ular methods.
2. Materials and methods
2.1. Materials
Osteosarcoma-derived cell line 143B.TK− (143B), immortalized
mammary epithelial cell line MCF-10A (10A), the breast cancer cell
lines MDA-MB-231 (231), MDA-MB-436 (436), and MDA-MB-453
(453) were procured from the American Type Culture Collection
(Manassas, VA). Carbonyl cyanide, p-(triﬂuoro-methoxy) phenylhydra-
zone, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT), rotenone, actinomycin D, ferric cyanide, NADH, glutamate,
malate, succinate, ADP, ATP monitoring kit andmouse β-actin antibody
were purchased from Sigma Chemical Co. (St. Louis, MO). Dulbecco's
modiﬁed Eagle's medium (DMEM), and fetal bovine serum were from
Invitrogen (Carlsbad, CA, USA). Antibody for P53 was purchased from
Cell Signaling Technology (Danvers MA). Antibodies for mitochondrial
proteinswere fromMitoSciences (Eugene, Oregon). SCO2 antibodywas
from Abcam, Inc. (Cambridge, MA). Secondary antibodies for rabbit and
mouse were from Bio-Rad (Hercules, CA).
2.2. Cell culture and the generation of ρ0 and cybrid cell lines
All breast cancer cell lines and transmitochondrial cybrid cell lines
were maintained in DMEM medium supplemented with 10% fetal
bovine serum, 2 mM L-glutamine, 100U/mL penicillin, 100 μg/mL
streptomycin, and 0.1 mg/mL bromodeoxyuridine (BrdU) according
to published protocols [22]. The 206 rho0 cell line derived from
osteosarcoma (143B) used as the mitochondria acceptor cell line
was kept in the same DMEM medium with the addition of 50 µg of
uridine/mL and 1 mM pyruvate [23]. Normal breast epithelial 10A
cells were cultured in mammary epithelial growth medium (Clo-
netics, San Diego, CA) supplemented with 100 ng/mL cholera toxin
(Calbiochem, La Jolla, CA) [24]. All cell cultures were grown in a
humidiﬁed incubator at 37 °C with 5% CO2. Medium was replenished
every 2 days.
Rho0 cell lineswere generated by treating 143B cells with ethidium
bromide according to published procedures [23]. The depletion of
mtDNA was conﬁrmed by real time quantitative PCR. Once the rho0
condition is established, rho0 clones were maintained in medium
without ethidium bromide as described above. Cybrids were gener-
ated by the fusion of rho0 cells with enucleated mitochondria in 45%
polyethylene glycol (MW 1450; Sigma cat P-5402) for 60 s according
to published procedures [25]. Following fusion, cells were plated in
selective medium lacking uridine. The cybrids generated containing
mitochondria derived from10A, 231, 436, and 453 cell lines are named
as 10A/143B, 231/143B, 436/143B, and 453/143B, respectively.
2.3. Sequence analysis of the entire mitochondrial genome and the
quantiﬁcation of tRNAThr and tRNASer using Northern blot analysis
Total genomic DNA was extracted from cultured cells using the
phenol/chloroform method according to standard protocols.
Sequence analysis was performed using BigDye terminator (version
3.1) cycle sequencing reagent kit on an ABI 3730 XLl DNA Analyzer
(Foster City, CA) as previously described [26]. Results from DNA
sequencing were compared with the published Cambridge Reference
Sequences from http://www.mitomap.org [11,27].
Isolation of total RNA and Northern blot analysis was carried
out according to published procedures [28]. Approximately 30 μg of
total RNA was subjected to Northern blotting and subsequently
hybridized with a 32P-end-labeled oligonucleotide probe speciﬁc totRNAThr (5′- TCATCTCCGGTTTACAAGACTG -3′) and tRNASer(UCN) (5′-
GTTGGCTTGAAACCAGC -3′). The amount of tRNAThr and tRNASer(UCN)
was normalized to the amount of nuclear-encoded 5 S ribosomal RNA
(the probe speciﬁc for 5 S rRNA was 5′-GGGTGGTATGGCCGTAGAC-3′
complementary to the 3′ region).
2.4. Cell viability measurement
The tetrazolium salt MTT was used to determine the cell viability
as previously described [29,30]. Brieﬂy, cells (5×103/well) were
seeded into 96-well plates and incubated in DMEM glucose-free
medium supplemented with 5 mmol/L galactose, 5 mmol/L Na-
pyruvate, and 10% FBS (DMEM-galactose medium) for 48 h. Absor-
bance of solubilized formazan salts was measured with a Tecan
Inﬁnite M200microplate reader (Mannedorf, Switzerland) at 570 nm.
2.5. Oxygen consumption
Cells were cultured for 3 days until approximately 80–90% con-
ﬂuent. Cells were then fed fresh medium 2 h before harvesting, then
trypsinized, washed in phosphate buffered saline (PBS), suspended in
growth medium and counted. Oxygen consumption was determined
by the Instech 600BH chamber system (Plymouth Meeting, PA, USA)
and Oxygen monitor 5300A (Yellow Springs, Ohio, USA). Typically,
5×106 cells were incubated in 1 mL growth medium at 37 °C. Oxygen
consumption was measured for each cell line. Respiration rates (nmol
atomic oxygen/min/million cells) were reported after normalization
of the polarographic oxygen consumption rates to cell number [31].
2.6. ATP synthesis
ATP synthesis was measured by a luciferin/luciferase assay
[15,32]. Brieﬂy, after the cells were trypsinized and resuspended
(7×106/mL) in buffer A [10 mmol/L KCl, 25 mmol/L Tris–HCl,
2 mmol/L EDTA, 0.1% bovine serum albumin, 10 mmol/L potassium
phosphate, 0.1 mmol/LMgCl2 (pH 7.4)], the cells were kept for 15min
at room temperature, followed by incubation in buffer A with 50 µg/
mL digitonin for 1 min. After quick centrifugation at low speed, the
cell pellet was resuspended in 100 µL of buffer A and 10 μL aliquots
were incubated with 5 mmol/L malate plus 5 mmol/L glutamate
(complex I-driven substrates), or with 10 mmol/L succinate (complex
II-driven substrate) plus 2 µg/mL rotenone, and 0.2 mmol/L ADP for
3 min in the presence or absence of 10 μg/mL oligomycin. The rate of
ATP synthesis is expressed as nmol ATP/min/mg protein.
2.7. Electron transport chain (ETC) analysis
Cells were sonicated and then used for electron transport chain
(ETC) enzyme assays. ETC enzymes were assayed at 30 °C using a
temperature-controlled spectrophotometer; Ultraspec 6300 pro, Bio-
chrom Ltd., (Cambridge, England). Each assay was performed in
triplicate. The activities of complex I (NADH:ferricyanide reductase),
complex II (succinate dehydrogenase), total and rotenone sensitive
complex I+III (NADH:cytochrome c reductase), complex II+III
(succinate:cytochrome c reductase), complex III (cytochrome c reduc-
tase), complex IV (cytochrome c oxidase), and CS (citrate synthase)
were measured using appropriate electron acceptors/donors according
to published procedures [33,34]. The increase or decrease in the
absorbance of cytochrome c at 550 nmwasmeasured for complex I+III,
II+III, III, and complex IV. The activity of complex I was measured by
oxidation of NADH at 340 nm. For complex II, the reduction of 2,6-
dichloroindophenol (DCIP) at 600 nm was measured. Citrate synthase
(CS)was used as amarker formitochondrial content andwasmeasured
by reduction of Ellman's reagent at 412 nm. Enzyme activities are
expressed both relative to total protein as nmol/min/mg protein and as
a ratio of CS activity.
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Cells were harvested and then collected by centrifugation at
600×g for 10 min at 4 °C. Cell pellets were washed once in PBS and
then resuspended in radioimmunoprecipitation assay (RIPA) buffer.
Total proteins were lysed as described elsewhere [35]. Samples were
then separated on 10% SDS-polyacrylamide electrophoresis gels and
electroblotted onto nitrocellulose membranes. Respiratory chain
proteins were detected by a monoclonal antibody at a dilution of
1:200. P53 and SCO2 antibody were diluted by 1:1000. Mouse
monoclonal antibody for β-actin was used at a dilution of 1:3000.
Horseradish peroxidase-labeled secondary antibody (1:3000) was
detected by enhanced chemiluminescence.
2.9. Statistical analysis
All analyses and experiments were repeated at least three times.
Results are presented as the mean±SD. Statistical analysis was
performed using Student's t test.
3. Results
3.1. Cancer cell viability reduced under metabolic stressful condition,
suggesting mitochondrial defects
To assess the efﬁciency of the utilization of oxidative phosphor-
ylation, normal (10A) and breast cancer (231, 436, and 453) cells and
their respective cybrids were grown in galactose medium, a
metabolically stressful condition. As depicted in Fig. 1A, the number
of viable cells was signiﬁcantly reduced when grown in galactose
medium compared to glucose medium except in normal epithelial
10A cells (Pb0.01). While in galactose medium, the number of viableFig. 1. A, Cell viability. Cells were incubated in glucose (grey) or galactose medium (black). Ce
MTT assay. MTT absorbance value at time 0 was considered as the 100% value of viable
consumption rates (nmol O/min/million cells) normalized to protein concentration. C and
driven by complex I (glutamate plus malate) or complex II (succinate with rotenone as inhib
mitochondrial ATP synthesis (nmol ATP/min/mg protein) represent the oligomycin sensit
containing cancer mitochondria, including cancer parental cells or their cybrids, when compcells in cell lines containing cancer mitochondria, including parental
and cybrid cells, were signiﬁcantly reduced (Pb0.01) when compared
to 10A parental cells or cybrids, with the exception of the 231/143B
cybrids, in which the number of viable cells was lower but not
statistically signiﬁcant. Cell viability assays were also performed by
measuring protease activities in the living cells and the results were
similar to MTT assays (data not shown). Since cybrid cells contain the
same nuclear genome and the only difference is in the origin of the
mitochondria, it can be inferred that the inability to utilize galactose
as the sole energy source by the mitochondrial oxidative phosphor-
ylation pathway was attributed to the altered mitochondria derived
from breast cancer cell lines.
3.2. Oxygen consumption rates are reduced in cancer cells and their
cybrids
To further investigate the defective respiratory chain function of
cancer mitochondria, oxygen consumption rates was measured
(Fig. 1B). It was found that oxygen consumption was reduced in the
parental breast cancer cell lines (231, 436 and 453)when compared to
10A cells (P values are 0.00002, 0.013, and 0.0008, respectively), and
in cybrids (436/143B or 453/143B) compared to 10A/143B (P values
are 0.003 and 0.002). However, in 231/143B cybrids, there was no
signiﬁcant difference in oxygen consumption rates suggesting that the
143B nucleus can partially compensate for the dysfunction of
mitochondria derived from the 231 cancer cell line.
3.3. Tumor mitochondria have reduced ATP synthesis rate
The efﬁciency of oxidative phosphorylation in cancer cells and
cybrids was analyzed by measuring ATP synthase activity driven by
complex I or complex II substrates. The rate of ATP synthesis driven byll viability was then determined after 48 h of growth in the indicated medium using the
cells. The number of viable cells was the average of three measurements. B, Oxygen
D, The rate of mitochondrial ATP synthesis was determined in the cells. ATP synthesis
itor for complex I) substrates with or without oligomycin was determined. The rates of
ive reaction. The asterisk, * (Pb0.05), indicates that the signiﬁcant difference in cells
ared to 10A parental cells or its cybrids. Each measurement was performed in triplicate.
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436, and 453 parental cancer cell lines compared to normal 10A cells (P
values are: complex I substrates: 0.00003, 0.003, 0.01 and complex II
substrates: 0.000005, 0.002, 0.0003, respectively). For the436/143Band
453/143B cybrids, the ATP synthesis rates were also signiﬁcantly lower
than that of 10A/143B cybrids (Pb0.05) (Fig. 1C–D). The ATP synthesis
rate in 231/143B cybrids was not signiﬁcantly reducedwhen compared
to 10A/143B.
3.4. Tumor mitochondria exhibit reduced respiratory chain complex
activities
Mitochondrial respiratory chain complex activities were also
investigated. As shown in Fig. 2, activities of complexes I, I+III, III,
and IV, as well as CS, were dramatically reduced in breast cancer cells
compared to those of normal (10A) cells (Pb0.05) (Fig. 2A–B). These
results are consistent with the defects that would affect overall
mitochondrial protein synthesis, for example, mutations in the tRNA
genes. Similarly, most complex activities were reduced in the cybrids,
but only the reduction in complex IV was statistically signiﬁcant in all
three cybrids containing cancer mitochondria compared to normal
10A mitochondria (Fig. 2C–D). Signiﬁcant reduction in complex I
activity was also observed in 436/143B and 453/143B cybrids
(Fig. 2C). Since the activities of most of the complexes containing
mitochondrial encoded subunits were reduced in 436/143B cybrids,
the results suggested that the mitochondrial dysfunction in the 436
cell line could possibly be caused by molecular defects in the
mitochondrial genome. In 231/143B cybrids, some of the mitochon-
drial complex activities (I, II+III, and III)were partially restored by the
donor nucleus of 143B cells. These results suggested that the
mitochondria derived from the 231 breast cancer cell line might
contain defects that were encoded by nuclear genes. The activity of
complex II, which does not contain any subunits encoded by
mitochondrial genome, exhibits no signiﬁcant difference among the
different cell lines, parental or cybrids. When the complex activitiesFig. 2. Electron transport chain assay. Complex activities were determined as described in
complex I in breast cancer cells. B, Activities of complex I+III total, I+III rotenone sensiti
Activities of complex I+III total, I+III rotenone sensitive, II, II+III, III, IV, and CS in cybrids
reductase, including total and rotenone sensitive; complex II: succinate dehydrogenase; com
complex IV: cytochrome c oxidase; CS: citrate synthase. Columns, mean; bars, SD; *, Pb0.0were normalized to complex II, the results were similar to those
normalized to protein concentrations (data not shown). Notably,
citrate synthase activity was reduced in the cybrids containing cancer
mitochondria when compared to 10Amitochondria, but the reduction
was not signiﬁcant. This was due to the fact that the cybrids were all of
the same nuclear background, unlike the breast cancer cells where the
CS activitywasmarkedly reduced in tumor cells compared to 10A cells.
3.5. Identiﬁcation of molecular defects in mitochondrial DNA
Sequencing of the entire mitochondrial genome of the breast
cancer cell lines and their cybrids revealed numerous polymorphisms
and neutral variants when compared to the Cambridge Reference
Sequence (Table 1). Identical mtDNA variants were also present in the
corresponding cybrid cell lines, conﬁrming that the mitochondria in
the cybrid cells were indeed derived from the original breast cancer
cell lines. Most of these variants have been reported to be benign.
However, two novel variants of potential pathogenic effect were
identiﬁed: a homoplasmic 15894GNA tRNAThr in the 231 breast cancer
cell line and a heteroplasmic 7458GNA in tRNASer(UCN) in the 436
breast cancer cell line (Fig. 3A–B). Potentially pathogenic mutations
were not found in the mitochondrial DNA from the normal breast
epithelial 10A cells or the 453 breast cancer cell line (Table 1).
The effect of 15894GNA and 7458GNA alterations on the synthesis
of tRNAThr and tRNASer(UCN) was investigated by Northern blot. The
steady-state amount of the mutant tRNAThr or tRNASer(UCN) was
quantiﬁed by normalization to the amount of nuclear-encoded 5S
rRNA. The results showed reduced tRNAThr in 231/143B cybrids (22%)
and tRNASer(UCN) in 436/143B cybrids (79%) compared to 10A/143B
cybrids without the tRNAThr or tRNASer(UCN) mutations. It was also
found that the steady-state amount of tRNAThr in the 453/143B cybrid
cells was about 57% compared to that of the wild type tRNAThr in the
control cybrids 10A/143B (Fig. 3C). The cause for this reduction is not
clear. This suggests that other factors might regulate the transcription
of tRNAThr in the 453/143B cybrids.the Materials and methods and normalized with protein concentration. A, Activity of
ve, II, II+III, III, IV, and CS in breast cancer cells. C, Activity of complex I in cybrids. D,
. Complex I: NADH: ferricyanide dehydrogenase; complex I+III: NADH: cytochrome c
plex II+III: succinate: cytochrome c reductase; complex III: cytochrome c reductase;
5.
Table 1
Mitochondrial DNA sequences of breast cancer cell lines and cybrids.
Mutations Gene Base change Codon AA change 10A 231 436 453 Reported in Mitomap
Haplogroup HV X H H
72TNC HV2 TNC − − + − Yes
73ANG HV2 ANG + + − + Yes
153ANG HV2 ANG − + − − Yes
185GNA HV2 GNA + − − − Yes
185GNA HV2 GNT − − − + Yes
195TNC HV2, OH TNC − + − − Yes
225GNA CSB1 GNA − + − − Yes
226TNCT CSB1 TNC − + − − Yes
228GNA CSB1 GNA + − − + Yes
241ANG mtTF1 binding ANG − − − − Yes
263ANG HV2 ANG + + + + Yes
295CNT mtTF1 binding CNT + − − + Yes
300_301het_insCC + − − − Yes
310TNC OH, CSB2 TNC + − − − Yes
310_311insC − − + − Yes
315_316insC OH, CSB2 insC − + − − Yes
462CNT d-loop CNT + − − − Yes
489TNC d-loop TNC + − − +(ht) Yes
514_515insAC − − + − Yes
750ANG MTRNR1 (12S) ANG + + + + Yes
751ANG MTRNR1 (12S) ANG − − + − Novel
1320GNAG MTRNR1 (12S) GNA − − + − Novel
1438ANG MTRNR1 (12S) ANG + + + + Yes
1719GNA 16S rRNA GNA − + − − Yes
2285TNC MTRNR2 (16S) TNC − − + − Novel
2706ANG MTRNR2 (16S) ANG + + − − Yes
3010GNA MTRNR2 (16S) GNA + − − − Yes
3915GNA ND1 GNA GGGNGGA G203G − − − + Yes
3992CNT ND1 CNT ACANATA T229M − − + − Yes
4216TNC ND1 TNC TATNCAT Y304H + − − +(ht) Yes
4769ANG ND2 ANG ATANATG M100M + + + + Yes
6221TNC COI TNC CCTNCCC P106P − + − − Yes
6249GNA COI GNA GCTNACT A116T + − − − Novel
6267GNA COI GNA GCANACA A122T − + − − Novel
6371CNT COI CNT TCCNTCT S156S − + − − Yes
7028CNT COI CNT GCCNGCT A375A + + − − Yes
7458GNAG MT-TS1 GNA − − +(ht) − Novel
8269GNA Non-coding GNA − − + − Yes
8860ANG ATP6 ANG ACANGCA T112A + + + + Yes
9123GNA MTATP6 GNA CTGNCTA L199L − − + − Yes
10044ANG tRNA Gly ANG − − + − Yes
10084TNC ND3 TNC ATCNACC I9T + − − − Yes
11251ANG ND4 ANG CTANCTG L164L + − − − Yes
11719GNA ND4 GNA GGGNGGA G320G + + − − Yes
11932CNT ND4 CNT ATCNATT I391I − + − − Novel
12612ANG ND5 ANG GTANGTG V92V + − − − Yes
12705CNT ND5 CNT ATCNATT I123I − + − − Yes
13020TNC ND5 TNC GGTNGGC G228G − − − − Yes
13135GNA ND5 GNA GCANACA A267T − + − − Yes
13708GNA ND5 GNA GCANACA A458T + − − − Yes
13966ANG ND5 ANG ACGNGCG T544A − + − − Yes
14365CNT ND6 CNT GTG-GTA(Rev) V103V − − + − Yes
14470TNC ND6 TNA GGANGGT G68G − + − − Novel
14766CNT CYTB CNT ACTNATT T7I − + − − Yes
15034ANG CytB ANG CTANCTG L96L − + − − Novel
15326ANG CYTB ANG ACANGCA T194A − − − + Yes
15894GNA MT-TT GNA − + − − Novel
16069CNT HV1 CNT + − − − Yes
16126TNC HV1 TNC + + − − Yes
16129GNC HV1 GNA − − − + Yes
16189TNA HV1 TNA − + − − Novel
16223CNT HV1 CNT − + − − Yes
16278CNT HV1 CNT − + − − Yes
16319GNA HV1 GNA + − − − Yes
16519TNC D-loop TNC − + − + Yes
Note. ht: heteroplasmy.
The two tRNA alterations of possible pathogenic signiﬁcance are in bold.
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parental breast cancer cells and cybrids
The amount of nuclear-encoded mitochondrial proteins, Core 2 and
FeS,was reduced inparental cancer cellswhen compared to normal 10Acells, suggesting a generalized reduction in mitochondrial respiratory
function in cancer cells. However, there is no signiﬁcantdifference in the
amount of proteins in the cybrid cells because they share the same
nuclear genes (Fig. 4A–C). The mitochondrial encoded proteins, ND6
and COX II (complex IV, cytochrome c oxidase subunit II), are reduced in
Fig. 3. The tRNAmutation and Northern blot analysis. A, Secondary structure of humanmt-tRNAThr in 231 breast cancer cells. B, Secondary structure of humanmt-tRNASer(UCN) in 436
breast cancer cells. C, Northern blot assay of mt-tRNAThr and mt-tRNASer(UCN) for the cybrids, including 10A/143B, 231/143B, 436/143B, and 453/143B.
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mitochondria derived from cancer cell lines, suggesting that mitochon-
drial protein synthesis is reduced in cancer cells (Fig. 4A, D, E).
Interestingly, the expression of SCO2, a nuclear-encoded complex IV
assembly factor and a downstream target for P53, is markedly reduced
in parental cancer cells, while their expression in the cybrids remains
unaffected (Fig. 4A, F). It should be noted that P53 ismutated in all three
breast cancer cell lines; a dominant negative mutation in 231 cell and
frame-shift null mutations in 436 and 453 cell lines. The mutant P53
protein is similarly over-expressed in 231/143B compared to 10A/143B
cybrids (Pb0.01). However, P53 expression was reduced in 436/143B
and 453/143B cybrids (Pb0.05) compared to 10A/143B cybrids
(Fig. 4A, G). These results suggest that signals of oncogenic properties
from cancer mitochondria can be transmitted to the nucleus to regulate
the nuclear gene expression.
4. Discussion
Somatic mtDNA alterations have been commonly observed in all
types of cancer tissues and cell lines [7–11,36–40]. However, a
majority of these somatic mtDNA changes are in the non-coding D-
loop regions or result in silent amino acid changes that do not have
any apparent effect on mitochondrial function. Only a fewmay harbor
identiﬁable pathogenic mutations. In addition, the methods used to
identify these somatic mtDNA alterations are limited to the detection
of homoplasmic or high heteroplasmic changes. Cancer mitochondria
may carry a collection of low heteroplasmic levels of random somatic
mtDNA mutations that are not detectable using current mutationdetection technologies. Thus, using cybrids containing mitochondria
derived from either cancer or normal breast epithelial cells in the
same nuclear background is crucial in detecting functional alterations
of cancer mitochondria. In this report, we establish that cybrids
containing mitochondria derived from breast cancer cells are unable
to survive under metabolically stressful conditions and that they
exhibit reduced oxygen consumption ability, ATP synthesis, and
electron transport chain activities. The reduction in mitochondrial
function in cancer cells is also demonstrated by the reduction of viable
cells when they are forced to depend on mitochondrial oxidative
phosphorylation as the sole source of energy supply under metabo-
lically stressful conditions (Fig. 1A).
Since the cybrids were generated by fusing the mitochondrial
depleted rho0 cells with enucleated breast cancer cells, followed by
propagation of selected colonies, the observed mitochondrial dysfunc-
tion in the cybrids suggests that there may be genomic changes in the
cancermitochondria. Subsequent sequencing analysis indeed identiﬁed
mutations in the tRNAThr and tRNASer(UCN) genes in 231 and 436 breast
cancer cell lines respectively. These mutations were shown to affect the
amount of corresponding tRNA and the levels of mitochondrial protein
synthesis (Figs. 3, 4). The accountability of the mitochondrial DNA
mutations for the observed mitochondrial dysfunction is further
substantiated by the inability of the donor nucleus from 143B cells to
fully rescue mitochondrial function. Mutations in the mitochondrial
genome were not found in 453 cells. Nevertheless, the amount of
tRNAThr and the level of mitochondrial encoded protein synthesis were
reduced. Since intact cancer mitochondria were used, this reduction
may be due to other unidentiﬁed mitochondrial associated factors or
Fig. 4. A, Western blot analysis. The proteins analyzed include C-V-α (complex V), Core 2 (complex III), FeS (complex II), ND6 (complex I), COX II (complex IV), SCO2, P53, and β-
actin. B–G, Signal intensities normalized to that of β-actin. Data shown are the mean±SD of triplicate assays. The asterisk, * (Pb0.05), ** (Pb0.01), indicates signiﬁcant difference of
protein expression in cells containing cancer mitochondria, including cancer parental cells or their cybrids, when compared to 10A parental cells or its cybrids.
35Y. Ma et al. / Biochimica et Biophysica Acta 1797 (2010) 29–37epigenetic changes. It is also possible that the observed mitochondrial
dysfunction reﬂects a collectionof lowheteroplasmic somaticmolecular
alterations that are beyond the current detection limit.Interestingly, the replacement of the cancer nucleus with the 143B
nucleus partially restored mitochondrial function in the 231/143B
cybrids, suggesting that a portion of the observed mitochondrial
36 Y. Ma et al. / Biochimica et Biophysica Acta 1797 (2010) 29–37deﬁciency may be contributed by nuclear gene alterations. In fact, all
three breast cancer cell lines harbor mutations in the P53 gene. Both
436 and 453 cells carry frame-shift truncation mutations; c.205ins7
and c.367del30, respectively [41,42]. These result in null mutations
with no P53 protein produced (Fig. 4A, G) [41,42]. Whereas a
missense dominant negative mutation, p.R280K [41] was found in the
P53 protein of 231 cells. This mutant protein is over-expressed
(Fig. 4A, G) in 231 cells.
The expression of human SCO2, an assembly factor for complex IV
(cytochrome c oxidase, COX), is regulated by P53 [20]. In breast
cancers, SCO2 levels are reduced compared to normal 10A cells
(Fig. 4A, F). However, with the 143B nucleus in the cybrid cells, the
expression of SCO2 is not reduced in cancer cybrids, conﬁrming that
the 143B cells expresswild type P53 andwild type SCO2 (Fig. 4A, F, G).
Our studies clearly demonstrate the cross-talk between the nuclear
and mitochondrial genomes. In the breast cancer cells, regardless of
gain-of-function or loss-of-function of P53 mutations, the expression
of SCO2 is reduced in cancer cells (Fig. 4A, F, G). However, in cybrid
cells with the same wild type nuclear background, levels of SCO2
remain constant regardless of their mitochondrial origin (cancer or
normal). This stems from the fact that both thewild type SCO2 and P53
are derived from the 143B nuclear background. Nevertheless, P53
protein levels are consistently increased in the 231 cybrids. These
results suggest that the changes in themitochondria of the 231 cell line
maintain the oncogenic property of over-expression of the P53 gene,
supporting the observation that the mitochondria is communicating
with the nucleus. On the other hand, in the cybrids, the over-expressed
P53 is thewild type protein that does not directly affect the expression
of the SCO2, a mitochondrial COX assembly protein. This regulatory
signal is sent from the nucleus to the mitochondria. Thus, the dual
genome cross-talk is bidirectional. The mechanism requires further
investigation.
In conclusion, we have demonstrated that mitochondria in cancer
cells have been altered, genetically and functionally. These alterations
can send signals to thenucleus,which in turncan regulate theexpression
of genes involved in energy metabolism and tumorigenic properties.
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